Fig. 3From: A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)Patient time on treatment. *Details presented in text. Part 1 = weekly NUC-3373 dosing on Days 1, 8, 15 and 22 of 28-day cycles. Part 2 = alternate weekly NUC-3373 dosing on Days 1 and 15 of 28-day cyclesBack to article page